GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers, announced on September 10, 2026, that it has requested a hearing before the Nasdaq Hearings Panel to appeal a delisting determination received on August 27, 2026. The determination relates to the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The hearing is scheduled for October 13, 2026, and the request has stayed any suspension or delisting action pending the hearing and any extension period the Panel may grant. As a result, GeoVax’s common stock is expected to continue trading on The Nasdaq Capital Market under the symbol “GOVX” at least through that period. At the hearing, the company intends to present its plan to regain and maintain compliance with Nasdaq listing standards.
David Dodd, Chairman and CEO of GeoVax, stated, “We remain committed to maintaining GeoVax’s Nasdaq listing and look forward to presenting our compliance plan to the Hearings Panel. Importantly, the Nasdaq process does not change our strategic priorities or our focus on execution.” This news matters because a potential delisting could affect investor confidence and access to capital, which is critical for a clinical-stage biotech. Maintaining the Nasdaq listing provides liquidity and visibility, essential for funding ongoing research and development. Dodd emphasized that the company continues to advance GEO-MVA toward its planned pivotal Phase 3 clinical program, pursue opportunities to strengthen manufacturing and global preparedness capabilities, and engage potential strategic, funding, and development partners.
GeoVax’s priority program is GEO-MVA, an investigational Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026 to address the need for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. The company also maintains a broader MVA-based vaccine platform and intellectual property portfolio addressing high-consequence infectious diseases and global health preparedness.
The implications of this announcement extend beyond GeoVax. The company’s progress in vaccine and immunotherapy development could contribute to global health security, particularly for mpox and smallpox, which are considered high-consequence infectious diseases. The emphasis on vaccine supply resilience and biodefense preparedness aligns with growing international priorities. For investors, the outcome of the Nasdaq hearing will be closely watched as a indicator of the company’s ability to navigate financial and regulatory challenges. GeoVax’s continued focus on strategic partnerships and funding opportunities underscores the need for capital to advance its pipeline. For more information, visit www.geovax.com.
Forward-looking statements in the release note various risks, including the ability to obtain acceptable clinical trial results, regulatory approvals, and sufficient capital. The company’s future success depends on these factors, and there is no guarantee that it will regain compliance with Nasdaq listing standards or achieve its development goals. Nonetheless, GeoVax remains focused on building long-term value from its vaccine and immuno-oncology programs while addressing near-term corporate and financing priorities.
